ArticleClinical ophthalmology (Auckland, N.Z.)2025
Perforating Scleral Vessels and Their Influence on Myopic Macular Neovascularization.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the relationship between the presence and spatial relationship of perforating scleral vessels (PSVs) to the neovascular membrane, as seen on spectral-domain optical coherence tomography (SD-OCT), in eyes with myopic macular neovascularization (mMNV), and their association with clinical, anatomical, and treatment-related features. Methods: This retrospective case series included patients from the Portuguese Retina Study Group registry (Retina.com.pt) with a diagnosis of mMNV and active follow-up at ULS-SJ. Clinical data were collected and SD-OCT macular scans reviewed to determine PSV presence and spatial relation to the neovascular membrane. Results: We analyzed 100 eyes from 83 patients. PSVs were identified in 69 eyes (69%), and in 47 of these (68%), they were in direct contact with the neovascular membrane. PSV presence was significantly associated with older age (p = 0.019, Cohen's d = -0.57), thinner choroid (p < 0.001, r = -0.34), and greater macular thickness at diagnosis (p = 0.009, Cohen's d = -0.58). It was also associated with a higher likelihood of anti-VEGF treatment switch (OR = 7.44, p = 0.022), but not with recurrence (OR = 1.30, p = 0.806), injection frequency (p = 0.258), or change in visual acuity (p = 0.093, r = 0.17). PSV-lesion contact was associated with older age (mean: 60.9 vs 49.8 years, p < 0.001, Cohen's d = 0.83) and thinner choroid (mean rank: 39.98 vs 56.02, p = 0.005, r = 0.29). Conclusion: PSVs were frequently observed in eyes with mMNV and were associated with older age, thinner choroid, and greater macular thickness at baseline, as well as a higher likelihood of requiring treatment switch. However, neither their presence nor lesion contact independently predicted a worse disease course or functional outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.